Skip to main content

Table 1 Clinical characteristics comparing treatment success group and treatment failure group

From: Prediction of treatment failure and compliance in patients with tuberculosis

 

Treatment success

(N = 50)

Treatment failure

(N = 52)

P-value

Age

44.0(31.5–65)

44.5(29.5–67)

0.84

Male sex

28(56.0%)

38(73.1%)

0.11

BMI

21.1 ± 2.88

20.9 ± 3.07

0.72

Smoking

  

0.67

 Current

10(20.0%)

13(25.0%)

 

 Ex-

10(20.0%)

7(13.5%)

 

 Never

30(60.0%)

32(61.5%)

 

Drinking

  

0.21

 Heavy

3(6.0%)

3(5.8%)

 

 Social

19(38.0%)

19(36.5%)

 

 None

24(48.0%)

30(57.7%)

 

Underlying disease

 Diabetes

5(10.0%)

4(26.9%)

0.041

 Lung ds

3(6.0%)

4(7.7%)

> 0.99

 Heart ds

1(2.0%)

3(5.8%)

0.24

 Liver ds

2(4.0%)

1(1.9%)

> 0.99

 Kidney ds

1(2.0%)

3(5.8%)

0.36

 Prev TB Hx

8(16.0%)

19(36.5%)

0.01

Symptom

 Cough/sputum

20(40.0%)

29(55.8%)

0.16

 Dyspnea

10(20.0%)

7(13.5%)

0.43

 Chest pain

7(14.0%)

3(5.8%)

0.20

 Hemoptysis

1(2.0%)

3(5.8%)

0.62

 Fever

5(10.0%)

3(5.8%)

0.48

 Weakness

0(0%)

1(1.9%)

> 0.99

 Weight loss

6(12.0%)

4(7.7%)

0.52

 Asymptomatic

17(34.0%)

15(28.8%)

0.73

Enrollment

 Newly diagnosed

42(84.0%)

29(55.8%)

 

 Recurred

8(16.0%)

12(23.1%)

 

 Retreatment

0(0%)

7(13.5%)

 

 Default

0(0%)

3(5.8%)

 

Social Hx

 Occupation

18(36.0%)

23(44.2%)

0.62

 Marriage

28(56.0%)

33(63.5%)

0.13

 Medicaid

6(12.0%)

1(1.9%)

0.06

CPA

 Normal

4(8.0%)

2(3.8%)

0.43

 Cavity (+)

8(17.0%)

26(50.0%)

0.001

 Unilateral

26(52%)

23(44.2%)

0.30

 Bilateral

17(34%)

27(51.9%)

 

AFB smear

 Positive

11(23.4%)

27(51.9%)

 

DST

  

< 0.001

 All sensitive

46(92.0%)

21(40.4%)

 

 R to INH

2(4.0%)

5(9.6%)

 

 R to RFP

1(2.0%)

5(9.6%)

 

 Any other R

1(2.0%)

2(3.8%)

 

Treatment regimen

 HREZ

38(76.0%)

40(76.9%)

 

 HRE

11(22.0%)

1(1.9%)

 

 Others

1(2.0%)

11(21.2%)

 

Drug compliance

 Good compliance

50(100%)

37(71.2%)

 

 Poor compliance

0(0%)

15(28.8%)

 
  1. BMI Body mass index, ds Disease, Hx History, R Resistance, INH Isoniazid, RFP Rifampin, MDR Multi-drug resistance